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Abstract – The inhibitory activities of microalgal extracts against the expression of three EBV antigens, latent membrane 
protein (LMP)1, Epstein-Barr nuclear antigen (EBNA)1 and Z Epstein-Barr reactivation activator (ZEBRA) were assessed 
by immunocytochemistry. The observation that the methanol extracts and their fractions from Ankistrodesmus convolu-
tus, Synechococcus elongatus and Spirulina platensis exhibited inhibitory activity against EBV proteins in three Burkitt’s 
lymphoma cell lines at concentrations as low as 20 µg/ml suggests that microalgae could be a potential source of antiviral 
compounds against EBV. 
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INTRODUCTION
Algae are a potential source of yet to be fully ex-
plored antiviral compounds. The sulfated polysac-
charides from the red algae Porphyridium sp., and 
the blue green algae Spirulina platensis were found 
to inhibit the replication of herpes simplex virus-1 
and -2 (HSV-1 and HSV-2), varicella zoster virus 
(VZV) and human immunodeficiency virus type 1 
(HIV-1) (Hayashi et al., 1996; Huleihel et al. 2001; 
Huleihel et al., 2002; Barron et al., 2008). The com-
pounds griffithsin and fucoidan isolated from the red 
seaweed Griffithsia sp. and brown algae, respectively, 
were found to inhibit the entry of human immu-
nodeficiency virus-1 (HIV-1) into host cells (Wang 
and Ng 2001; Hayashi et al., 2008; Hidari et al., 2008; 
Micewicz et al., 2010). Despite many antiviral studies 
on algal compounds, there are few reports about the 
effects of these compounds against the Epstein-Barr 
virus (EBV).
The  EBV  is  an  etiological  factor  in  Burkitt’s 
lymphoma  (BL)  and  other  EBV-related  malignan-
cies, such as nasopharyngeal carcinoma, Hodgkin’s 
disease  and  infectious  mononucleosis  (Rickinson 
and Kieff, 2006; Rezk and Weiss, 2007). During la-
tent infection, several of the nine viral latent gene 
products, such as the Epstein-Barr nuclear antigen 1010 YIH YIH KOK ET AL.
1 (EBNA1) and latent membrane proteins 1 (LMP1), 
are  expressed  to  transform  and  immortalize  lym-
phoblastoid cell lines (Farrell 1995; Thorley-Lawson 
et al., 2008). LMP1 plays a crucial role in enhancing 
cell proliferation and providing an oncogenic effect 
by activating nuclear factor (NF) kappa B (κB) which 
upregulates anti-apoptotic genes (Fries et al., 1996; 
Luftig et al., 2004). On the other hand, EBNA1 acti-
vates the initiation of EBV DNA replication in host 
cells, and partitions the viral episomes during cell di-
vision for long-term plasmid maintenance (Hung et 
al., 2001). EBNA1 also confers resistance to apopto-
sis by upregulating the apoptotic suppressor protein 
gene (Lu et al., 2011). The reactivation of EBV from 
latency is initiated via activation of the expression of 
the immediate-early BZLF1 gene that encodes for 
the Z Epstein-Barr replication activator (ZEBRA) or 
Zta (Countryman and Miller, 1985).
At present, there is no specific approved drug 
against EBV (Gershburg and Pagano, 2005). In clini-
cal  applications,  non-EBV  specific  antiviral  drugs 
are used to treat EBV-associated diseases. Acyclovir 
is used to inhibit replication of the virus by target-
ing DNA polymerase (Elion, 1993). Hence, there is 
great interest in exploring natural compounds for 
their anti-EBV potential. To date, several molecules 
that display anti-EBV properties have been isolated 
from  higher  plants.  Epigallocatechin  gallate  from 
green tea, auraptene and umbelliprenin from Ferula 
sp., resveratrol from grapes, as well as the ethanol 
extracts from Polygonum cuspidatum and Chrysan-
themum indicum, inhibit the EBV lytic cascade by in-
hibiting EBV proteins (Chang et al., 2003; Iranshahi 
et al., 2008; Yiu et al., 2010; Yiu et al., 2011; Kim et 
al., 2012).
Our previous report showed the microalgae also 
contained  bioactive  anti-EBV  compounds  (Kok  et 
al., 2011). The methanol extracts from Ankistrodes-
mus convolutus, Synechococcus elongatus and Spiruli-
na platensis were found to inhibit the release of EBV 
from BL cell lines, Akata, B95-8 and P3HR-1. We in-
vestigated whether these algal extracts inhibited the 
release of cell-free EBV after viral antigen expression 
in BL cells. The objective of this study was to assess 
the  inhibitory  activities  of  methanol  extracts  and 
their fractions from Ankistrodesmus convolutus, Syn-
echococcus elongatus and Spirulina platensis against 
the expression EBV proteins EBNA1, LMP1 and ZE-
BRA in lymphoblastoid cells. 
MATERIALS AND METHODS
Microalgae cultures
Three  strains  of  microalgae  were  obtained  from 
the  University  Malaya  Algae  Culture  Collection 
(UMACC): Spirulina (Arthrospira) platensis UMACC 
161, Synechococcus elongatus UMACC 105 and An-
kistrodesmus  convolutus  UMACC  101  (Phang  and 
Chu,  1999).  Spirulina  platensis  and  Synechococcus 
elongatus were grown in Kosaric medium. and An-
kistrodesmus convolutus UMACC 101 was grown in 
Bold’s Basal Medium (BBM) (Nicols and Bold, 1965; 
Zarrouk, 1996). The cultures were placed on shelves 
illuminated with fluorescent lamps (42 µmol/m2/s, 
12:12 h light-dark cycle) in a controlled-temperature 
(28oC) room.
Extract preparation
The algal extracts were prepared as described previ-
ously (Kok et al., 2011). A bioassay-guided fractiona-
tion approach was used to test the antiviral activity of 
the extracts. Only extracts and fractions that exhib-
ited strong inhibitory activities against the release of 
cell-free EBV shown in the previous study were fur-
ther tested for their inhibitory activities against the 
expression of EBV antigens in BL cells (Table 1). The 
concentrations tested were much lower than the val-
ues for the inhibition concentration (IC)50 obtained 
previously. Cells treated with commercial antiviral 
drugs such as acyclovir and foscarnet (Sigma) (0-100 
µg/ml) served as positive controls.
Lymphoblastoid cell cultures
Three  EBV-positive  Burkitt’s  lymphoma  (BL)  cell 
lines were used: Akata, B95-8, and P3HR-1. All cell 
lines  were  maintained  in  Roswell  Park  Memorial 
Institute (RPMI) 1640 medium supplemented with INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1011
10% (v/v) fetal bovine serum (FBS) and 50 IU pen-
icillin-streptomycin, and grown in a CO2 incubator. 
B95-8  and  P3HR-1  cells  were  chemically  induced 
using  0.2%  (v/v)  phorbol  12-myristate-13-acetate 
(32 µM) and 1% (v/v) sodium N-butyrate (0.3 µM). 
Akata cells were induced into a lytic cycle with 0.8% 
(v/v) rabbit antiserum to human IgG (ICN Pharma-
ceuticals, USA).
Immunocytochemistry analysis
After 72 h of incubation with the microalgal extracts, 
the  BL  cells  were  washed  twice  with  phosphate 
buffer saline (PBS). A small drop of the suspension 
(106 cells/ml) was smeared on a Teflon-coated multi-
welled slide and dried fixed with cold acetone. The 
fixed slides were boiled in 10 mM citrate buffer, pH 
6.0 for 4 min and rinsed with distilled water. Hydro-
gen peroxide (3%) was added to the wells and then 
washed with distilled water followed by PBS.
Monoclonal mouse anti-Epstein-Barr virus an-
tibodies,  LMP1  clone  S12  (BD  Bioscience,  USA), 
EBNA1  (Calbiochem,  USA)  and  BZLF1  protein, 
ZEBRA  clone  BZ.1  (DakoCytomation,  Denmark) 
were diluted to 1:100 with PBS containing 10% nor-
mal goat serum before addition to the samples in the 
wells. The samples were left at 37oC for 4 h to allow 
hybridization to occur. The slides were then washed 
in PBS thrice (5 min each). HRP-conjugated anti-
mouse polymer (DakoCytomation, Denmark) was 
added to the wells and left at 37oC for 1 h. The cells 
Table 1. Microalgal extracts and fractions used for testing against the expression of EBV antigens in the three Burkitt’s Lymphoma cell 
lines. The extracts and fractions were selected based on their positive activities against the release of cell-free EBV DNA.
Yield Cell Lines
Extract/Fraction (µg/mg dry weight) Akata B95-8 P3HR-1
Crude extracts
Ankistrodesmus convolutus (AC) methanol extract 178.3 + + +
Synechococcus elongatus (SC) methanol extract 177.5 + + +
Spirulina platensis  (SP) methanol extract 86.9 + + +
Column chromatography fractions
ACF2 20.4 + - -
ACF3 23.2 + - -
ACF1 7.2 - + -
ACF5 8.3 - + -
ACF6 22.8 - + -
SEF1 12.0 - + +
SEF3 3.9 - +
+
HPLC subfractions
ACF2’a 171 + - -
ACF2’c 144 + - -
ACF2’d 89 + - -
ACF2’e 50 + - -
ACF2’f 20 + - -
ACF1’a 95 - + -
ACF1’b 38 - + -
SEF1’a 149 - - +
SEF1’c 315 - - +
SEF1’d 66 - - +
SEF3’a 54 - - +
SEF3’c 182 - - +
+ expression of viral proteins tested; - expression of viral proteins were not tested; F fractions collected from silica gel column; ’ subfrac-
tions collected from HPLC column1012 YIH YIH KOK ET AL.
were washed in PBS with slow shaking for 5 min. The 
substrate 3,3-diaminobenzidine (DAB) (DakoCyto-
mation, Denmark) was used for color development. 
Unstained cells were counter-stained with hematoxy-
lin. After washing, the excess hematoxylin, the slides 
were dipped in ammonia water (10%) for 10 s. The 
dried slides were mounted using Depax and covered 
with cover slips. The slides were examined under the 
light microscope (Nikon Eclipse 80i). A minimum 
of 400 cells were scored. The percentage of cells ex-
pressing the targeted of protein was calculated using 
the following equation:
Percentage of cells that express the targeted pro-
tein (%) = number of positively stained cells x 100% 
Total number of cells counted in a population
Statistical analysis
Data are presented as the means with standard devia-
tion derived from duplicate samples from two inde-
pendent experiments. The data were analyzed using 
one-way analysis of variance (ANOVA), followed by 
Duncan’s Multiple Range test using Statistica soft-
ware (Version 5). A p value < 0.05 was regarded as 
statistically significant.
RESULTS
Inhibitory activity of the methanol extracts
The  inhibitory  effects  of  the  microalgal  extracts 
against the expression of EBV viral proteins were as-
sessed by determining the number of cells express-
ing the proteins in a cell population, estimated by 
immunocytochemistry. Cells that expressed the an-
tigens showed positive binding and stained brown 
compared to the background that appeared blue. The 
percentage of positively stained cells in the treated 
groups was compared to the negative control. 
Different BL cell lines expressed different levels 
of EBV antigens. The percentages of Akata cells ex-
pressing EBNA1, LMP1 and ZEBRA in the negative 
control population were 35.6%, 18.1% and 32.5%, 
respectively (Fig. 1). In Akata cells, of the three EBV 
proteins  studied,  the  number  of  ZEBRA  positive 
Akata cells was decreased the most, from 32.5% to 
less than 7%. The methanol extract from Ankistrodes-
mus convolutus (100 µg/mL) reduced the percentage 
of  cells  expressing  ZEBRA  most  effectively,  from 
32.5% to 3.3% (Fig. 1c). 
The percentages of EBNA1 and LMP1 positive 
B95-8 cells were relatively low compared to Akata 
and P3HR-1 cells (Figs. 2a, 2b). The methanol extract 
from Synechococcus elongatus (100 µg/ml) caused a 
reduction of EBNA1 positive BL cells by more than 
60%  in  all  three  BL  cells.  The  microalgal  extracts 
reduced the number of ZEBRA positive B95-8 cells 
from 25% to less than 8.5% (Fig. 2c).
In P3HR-1 cells, the percentage of LMP1 positive 
cells compared to non-treated cells was reduced by 
66% after the treatment with 100 µg/ml of the metha-
nol extract from Spirulina platensis (Fig. 3b). In con-
trast, 100 µg/ml of the methanol extract from Ank-
istrodesmus convolutus and Synechococcus elongatus 
decreased the percentage of ZEBRA positive cells by 
more than 66% (Fig. 3c). In addition, the methanol 
extract from Spirulina platensis (100 µg/mL) reduced 
the percentage of EBNA1 positive P3HR-1 cells by 
75% when compared to the negative control.
All three microalgal methanol extracts decreased 
the  percentages  of  LMP1  positive  BL  cells  by  46-
69% when compared to the non-treated group. The 
microalgal methanol extracts reduced the expression 
of ZEBRA more than 50% in all three Akata, B95-8 
and P3HR-1 cell lines.
Inhibitory activity of silica gel fractions
Some of the methanol extracts exhibited inhibitory 
activity after fractionation. The fraction ACF2 (20 
µg/mL) reduced EBNA1 positive Akata cells by 70%, 
whereas the crude methanol extract of Ankistrodes-
mus convolutus did not display any inhibitory activ-
ity against EBNA1 (Fig. 4a).
As shown in Fig. 5, ACF1, ACF5, ACF6, SEF1 
and SEF3 did not significantly (p>0.05) reduce the INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1013
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Fig. 1.  Percentage of EBV antigen-positive Akata cells aft  er treatments with the extracts for 72 h, determined by immunocytochemistry. 
Th   e percentage of positively staining cells relative to the whole cell population was determined as described in the Materials and Meth-
ods. A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two independent experiments performed in duplicate. Asterisks show 
signifi  cant diff  erences relative to the control (p< 0.05).1014 YIH YIH KOK ET AL.
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Fig. 2. Percentage of EBV antigen positive B95-8 cells aft  er treatment with extracts for 72 h, determined by immunocytochemistry. Th   e 
percentage of positive-staining cells relative to the whole cell population was determined as described in the Materials and Methods. 
A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two independent experiments performed in duplicate. Asterisks show 
signifi  cant diff  erences relative to the control (p< 0.05). INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1015
Fig. 3. Percentage of EBV antigens positive P3HR-1 cells treated with microalgae extracts for 72 determined by immunocytochemistry. 
Th   e percentage of positive-staining cells was determined as described in the Materials and Methods. A) EBNA1; B) LMP1; C) ZEBRA. 
Values shown are means of two independent experiments performed in duplicate. Asterisks show signifi  cant diff  erence relative to the 
control at (p< 0.05). 
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Fig. 4. Percentage of EBV antigen positive Akata cells aft  er treatments with fractions (obtained aft  er column chromatography) of the 
methanol extracts from Ankistrodesmus convolutus(AC), ACF2 and ACF3 for 72 h, determined by immunocytochemistry. Th   e percent-
age of positive-staining cells was determined as described in the Materials and Methods. Th   e background was stained with hematoxylin. 
A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two independent experiments performed in duplicate. Asterisks show 
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Fig. 5. Percentage of EBV antigens positive B95-8 cells treated with fractions of the methanol extracts (obtained aft  er column chroma-
tography) from Ankistrodesmus convolutus(AC) and Synechococcus elongatus (SE) ACF1, ACF5, ACF6, SEF1 and SEF3 for 72 h, deter-
mined by immunocytochemistry. Th   e percentage of positive-staining cells was determined as described in the Materials and Methods. 
Th   e background was stained with hematoxylin. A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two independent experi-
ments performed in duplicate. Asterisks show signifi  cant diff  erences relative to the control (p< 0.05).
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Fig. 6. Percentage of EBV antigens positive P3HR-1 cells treated with fractions of the methanol extracts (obtained aft  er column chro-
matography) from Ankistrodesmus convolutus(AC) and Synechococcus elongatus (SE) SEF1 and SEF3 for 72 h, determined by immuno-
cytochemistry. Th   e percentage of positive-staining cells was determined as described in the Materials and Methods. Th   e background 
was stained with hematoxylin. A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two independent experiments performed 
in duplicate. Asterisks show signifi  cant diff  erences relative to the control (p< 0.05).INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1019
Fig. 7. Percentage of EBV antigens positive Akata cells treated with HPLC subfractions of ACF2- ACF2’a, ACF2’c, ACF2’d, ACF2’e and 
ACF2’f for 72 h, determined by immunocytochemistry. Th   e percentage of positive-staining cells was determined as described in the 
Materials and Methods. Th   e background was stained with hematoxylin. A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of 
two independent experiments performed in duplicate. Asterisks show signifi  cant diff  erences relative to the control (p< 0.05).
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Fig. 8. Percentage of EBV antigens positive B95-8 cells treated with HPLC sub-fractions of ACF1- ACF1’a and ACF1’b for 72 h, deter-
mined by immunocytochemistry. Th   e percentage of positive-staining cells was determined as described in the Materials and Methods. 
Th   e background was stained with hematoxylin. Th   e background was stained with hematoxylin. A) EBNA1; B) LMP1; C) ZEBRA. Values 
shown are means of two independent experiments performed in duplicates. Asterisks show signifi  cant diff  erences relative to the control 
(p< 0.05)..INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1021
Fig. 9. Percentage of EBV antigens positive P3HR-1 cells treated with HPLC sub-fractions of SEF1- SEF1’a, SEF1’c, SEF1’d, SEF3’a and 
SEF1’c for 72 h, determined by immunocytochemistry. Th   e percentage of positive-staining cells was determined as described in the Ma-
terials and Methods. Th   e background was stained with hematoxylin. A) EBNA1; B) LMP1; C) ZEBRA. Values shown are means of two 
independent experiments performed in duplicate. Asterisks show signifi  cant diff  erences relative to the control (p< 0.05).
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expression of the three antigens in B95-8 cells, al-
though  they  showed  antiviral  activity  in  the  real 
time PCR assay in our previous work (Kok et al., 
2011).  SEF3  reduced  significantly  (p>0.05)  the 
number of EBNA1 positive P3HR-1 cells at 2.5-20 
µg/ml, while SEF1 (20 µg/ml) reduced the number 
of  EBNA1  and  ZEBRA  positive  P3HR-1  cells  by 
40.4% and 41.4%, respectively. (Figs. 6a and 6c, re-
spectively).
Inhibitory activities of HPLC subfractions
The HPLC subfractions of ACF2 showed different 
activities against the expression of the three antigens 
in Akata cells (Fig. 7). The bioactivities of ACF2’a, 
ACF2’c, ACF2’d, ACF2’e and ACF2’f were highest at 
20 µg/ml, as they reduced by 45-83% the number of 
EBNA1 positive Akata cells as compared to the con-
trol (Fig. 7a). All the HPLC sub-fractions (10 µg/
ml)  significantly  reduced  (p<0.05)  the  percentage 
of LMP1-positive Akata cells by 45-63% (Fig. 7b). 
ACF2’a and ACF2’c at 10 µg/ml caused a considera-
ble 65% reduction in the number of ZEBRA positive 
Akata cells (Fig. 7c). Clearly, the inhibitory activities 
in Ankistrodesmus convolutus against ZEBRA were 
preserved after fractionation. 
The HPLC subfractions of the extract from Ank-
istrodesmus convolutus, ACF1’a and ACF1’b, signifi-
cantly reduced (p<0.05) the number of ZEBRA-posi-
tive B95-8 cells, but not EBNA1- and LMP1-contain-
ing cells (Fig. 8). Nevertheless, the percentage of ZE-
BRA-positive B95-8 cells was lower after treatment 
with ACF1’b compared to ACF1’a (Fig. 8c). None of 
the of the HPLC subfractions of the extracts of Syn-
echococcus  elongatus  were  capable  of  lowering  the 
expression of the three antigens in P3HR-1 cells (Fig. 
9). The only active HPLC subfraction that showed 
remarkable  inhibition  activity  was  SEF3’a  (20  µg/
ml), which reduced the number of ZEBRA-positive 
P3HR-1 cells by 67.8% compared to the control (Fig. 
9c). Overall, the subfractions from the microalgal 
extracts,  ACF1’a,  ACF1’b,  ACF2’a,  ACF2’c,  SEF1’d 
and SEF3’a, seemed to be more active in inhibiting 
the expression of the EBV lytic protein ZEBRA in BL 
cells (Figs. 7c, 8c, 9c).
DISCUSSION
The  microalgal  extracts  tested  herein  previously 
showed inhibitory activity against the release of cell-
free EBV DNA. Our aim was to examine further the 
antiviral effects of the the extracts. Generally, they 
showed inhibitory activities against the expression of 
EBV proteins, observed as a reduction in the num-
bers of cells expressing the EBV proteins. The per-
sistency, replication and gene expression of EBV is 
dependent on the binding of EBNA1 to the origin 
of plasmid replication (OriP), which serves to main-
tain the EBV episome in dividing cells (Hung et al., 
2001). Therefore, EBNA1 is an attractive target for 
potential EBV inhibitors because of its critical role in 
EBV-associated disorders. In this study, the methanol 
extract from Ankistrodesmus convolutus, Synechococ-
cus  elongatus  and  Spirulina  platensis  (100  µg/mL) 
exhibited a significant reduction of EBNA1-positive 
BL cells (by more than 60%). These microalgal ex-
tracts could decrease the presence of EBV episomes 
in new daughter cells and terminate latent EBV in-
fection by inhibiting EBV episome replication. Per-
sistence of the EBV genome and the lytic cascade 
can be obstructed via downregulation of the latency-
associated promoter Qp (Kieff and Rickinson, 2006). 
This causes fewer EBV virions to be assembled and 
released. In our previous study where we assessed the 
copy number of cell-free EBV DNA, ACF2 and its 
HPLC subfractions reduced the number of cell-free 
EBV DNA by 50% at concentrations between 1.6-4.2 
µg/ml (Kok et al., 2011). 
Recently, LMP1 was proposed as a therapeutic 
target in EBV-associated disorders (Hannigan and 
Wilson, 2010). The microalgal crude extract exhib-
ited  >30%  inhibitory  activity  against  LMP1  in  all 
three cell lines, except Ankistrodesmus convolutus in 
B95-8 cells. These compounds could block the NF-
κB pathway and disrupt cell survival, leading to cell 
death (Lavorgna and Harhaj, 2012). This is in agree-
ment with our previous study where the HPLC sub-
fractions ACF2’c and ACF2’d reduced the number of 
viable Akata cells by about 50% (Kok et al., 2011). We 
also speculate that the reduction of LMP1 activates 
the DNA repair pathway in host cells, leading to deg-INHIBITORY ACTIVITY OF MICROALGAL EXTRACTS AGAINST THE EXPRESSION OF EPSTEIN-BARR VIRUS (EBV) 1023
radation of EBV viral DNA and the resulting release 
of lower amounts of cell-free EBV. This was shown 
in our previous work where the methanol crude ex-
tracts, ACF2’a, ACF2’c, ACF2’d, ACF2’e and ACF2’f, 
inhibited the release of cell-free EBV DNA by 50% at 
concentrations lower than 20 µg/ml.
All three microalgal extracts and some of their 
HPLC subfractions lowered the number of ZEBRA-
positive cells by about 60% in all three Akata, B95-8 
and P3HR-1 cell lines. ZEBRA is a crucial lytic trans-
activator in the EBV life cycle. Therefore, these ex-
tracts could switch off the lytic transactivation cycle 
in BL cells by blocking the activation of the BZLF1 
gene, thus preventing the switch from latent to lytic 
cycle gene expression. Consequently, this leads to a 
decrease in the numbers of assembled and released 
viral particles (Feederle et al., 2000; El-Guindy et al., 
2006). This explains the lower copy number of cell-
free EBV released by the host cell after exposure to 
the methanol extract of Ankistrodesmus convolutus 
that was reported previously.
The mechanisms responsible for the induction of 
lytic EBV are complex and involve calcium-depend-
ent mechanisms, protein kinase C (PKC), p38, c-jun 
N-terminal kinase (JNK) and mitogen activated pro-
tein kinases (MAPK) (Israel and Kenney, 2003). Be-
side BZLF1, BRLF1 mediates the switch form latent 
to lytic viral replication (Miller and El-Guindy, 2002). 
Therefore, the effects of the microalgal extracts on 
the cell cycle of BL cells warrants further studies.
CONCLUSION
Methanolic  microalgal  extracts  and  their  subfrac-
tions obtained after HPLC reduced the number of 
LMP1-, EBNA1- and ZEBRA-positive BL cells, sug-
gesting that these preparations could serve as sources 
of potential anti-EBV agents.
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